Prognostic impact of N1 lymph node micrometastasis in T1-2a Non-small cell Lung Cancer.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
617 patients, 550 had no lymph node metastasis, 22 had N1 micrometastasis, and 45 had N1 macrometastasis.
I · Intervention 중재 / 시술
complete resection-including lobectomy or more extensive procedures-with systematic lymph node dissection between 2000 and 2015
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
추출되지 않음
OpenAlex 토픽 ·
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
Lung Cancer Treatments and Mutations
[OBJECTIVES] Lymph node micrometastasis, defined as tumor deposits <2 mm, has been proposed as an adverse prognostic factor in early-stage non-small cell lung cancer (NSCLC), but its clinical signific
- p-value P < 0.001
- p-value P = 0.007
- 95% CI 1.388-4.829
APA
Hiroyasu Koga, Tetsukan Woo, et al. (2026). Prognostic impact of N1 lymph node micrometastasis in T1-2a Non-small cell Lung Cancer.. Cancer treatment and research communications, 47, 101201. https://doi.org/10.1016/j.ctarc.2026.101201
MLA
Hiroyasu Koga, et al.. "Prognostic impact of N1 lymph node micrometastasis in T1-2a Non-small cell Lung Cancer.." Cancer treatment and research communications, vol. 47, 2026, pp. 101201.
PMID
41990633 ↗
Abstract 한글 요약
[OBJECTIVES] Lymph node micrometastasis, defined as tumor deposits <2 mm, has been proposed as an adverse prognostic factor in early-stage non-small cell lung cancer (NSCLC), but its clinical significance remains unclear. This study aimed to evaluate the prognostic impact of N1 micrometastasis in patients with T1-2a NSCLC.
[PATIENTS AND METHODS] We retrospectively analyzed patients with pathologically confirmed T1-2a NSCLC who underwent complete resection-including lobectomy or more extensive procedures-with systematic lymph node dissection between 2000 and 2015. N1 micrometastasis was identified by cytokeratin immunohistochemistry and quantified using digital slide analysis.
[RESULTS] Among 617 patients, 550 had no lymph node metastasis, 22 had N1 micrometastasis, and 45 had N1 macrometastasis. In univariate analysis, patients with N1 micrometastasis had significantly worse recurrence-free survival (RFS) and overall survival (OS) compared with those without lymph node involvement (5-year RFS: 53.3 % vs. 85.1 %, P < 0.001; 5-year OS: 61.5 % vs. 87.0 %, P = 0.007). Multivariate analysis identified N1 micrometastasis as an independent adverse prognostic factor for RFS (HR 2.589, 95 % CI 1.388-4.829, P = 0.003) and OS (HR 2.179, 95 % CI 1.052-4.513, P = 0.036). Furthermore, stabilized inverse probability of treatment weighting (IPTW)-adjusted analysis confirmed significantly worse RFS (HR 2.992, 95 % CI 1.276-7.018, P = 0.012), whereas the difference in OS did not reach statistical significance (HR 2.207, 95 % CI 0.855-5.698, P = 0.102).
[CONCLUSIONS] N1 lymph node micrometastasis is a significant negative prognostic factor for RFS in T1-2a NSCLC. These findings support further prospective studies to validate its role in guiding treatment decisions for early-stage NSCLC.
[SHORT ABSTRACT] We retrospectively analyzed patients with pathologically confirmed T1-2a non-small cell lung cancer (NSCLC) who underwent complete resection with systematic lymph node dissection. Multivariate and stabilized inverse probability of treatment weighting (IPTW)-adjusted analyses identified N1 lymph node micrometastasis as a significant adverse prognostic factor for postoperative recurrence-free survival (RFS).
[PATIENTS AND METHODS] We retrospectively analyzed patients with pathologically confirmed T1-2a NSCLC who underwent complete resection-including lobectomy or more extensive procedures-with systematic lymph node dissection between 2000 and 2015. N1 micrometastasis was identified by cytokeratin immunohistochemistry and quantified using digital slide analysis.
[RESULTS] Among 617 patients, 550 had no lymph node metastasis, 22 had N1 micrometastasis, and 45 had N1 macrometastasis. In univariate analysis, patients with N1 micrometastasis had significantly worse recurrence-free survival (RFS) and overall survival (OS) compared with those without lymph node involvement (5-year RFS: 53.3 % vs. 85.1 %, P < 0.001; 5-year OS: 61.5 % vs. 87.0 %, P = 0.007). Multivariate analysis identified N1 micrometastasis as an independent adverse prognostic factor for RFS (HR 2.589, 95 % CI 1.388-4.829, P = 0.003) and OS (HR 2.179, 95 % CI 1.052-4.513, P = 0.036). Furthermore, stabilized inverse probability of treatment weighting (IPTW)-adjusted analysis confirmed significantly worse RFS (HR 2.992, 95 % CI 1.276-7.018, P = 0.012), whereas the difference in OS did not reach statistical significance (HR 2.207, 95 % CI 0.855-5.698, P = 0.102).
[CONCLUSIONS] N1 lymph node micrometastasis is a significant negative prognostic factor for RFS in T1-2a NSCLC. These findings support further prospective studies to validate its role in guiding treatment decisions for early-stage NSCLC.
[SHORT ABSTRACT] We retrospectively analyzed patients with pathologically confirmed T1-2a non-small cell lung cancer (NSCLC) who underwent complete resection with systematic lymph node dissection. Multivariate and stabilized inverse probability of treatment weighting (IPTW)-adjusted analyses identified N1 lymph node micrometastasis as a significant adverse prognostic factor for postoperative recurrence-free survival (RFS).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A case of pulmonary mucosa-associated lymphoid tissue lymphoma with plasmacytic differentiation and amyloid deposition: case report and literature review.
- Dosimetric analysis and clinical outcomes including adverse events in postoperative breast cancer irradiation involving the internal mammary lymph node region using Hybrid VMAT.
- DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report.
- Correlation of E-cadherin, vimentin, CD206, programmed cell death receptor 1, and programmed cell death ligand 1 expressions with clinicopathological factors and prognosis in oral squamous cell carcinoma.
- Immune Profiling the Axilla with Fine Needle Aspiration Is Feasible to Risk-Stratify Breast Cancer.
- [Adrenocortical carcinoma (ACC): current surgical treatment strategies].